Trials / Completed
CompletedNCT02314403
Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a haplo-identical related donor. An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Belatacept | A selective T-cell (lymphocyte) costimulation blocker |
| DRUG | ATG | A T-Cell Depleting Agent |
| DRUG | Rituximab | B-Cell Depleting Agent |
| RADIATION | Total Body Irradiation | |
| RADIATION | Thymic Irradiation | |
| PROCEDURE | Combined Bone Marrow/Kidney Transplantation |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2021-03-01
- Completion
- 2021-07-01
- First posted
- 2014-12-11
- Last updated
- 2021-10-25
- Results posted
- 2021-09-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02314403. Inclusion in this directory is not an endorsement.